Table 2.
Characteristics of patients from CALGB 50402 and CALGB 50701
| Treatment Protocol | p-value* | ||
|---|---|---|---|
| Rituximab + Epratuzimab | Rituximab + Galiximab | ||
| Number of patients | 55 | 46 | |
| Ethnicity | 1.00 | ||
| Caucasian | 50/53 (94.3%) | 45 (97.8%) | |
| Non-Caucasian | 3/53 (5.7%) | 1 (2.2%) | |
| Median age, y (range) | 54 (32–90) | 58 (22–84) | 0.75 |
| Female Gender | 32 (58.1%) | 16 (34.8%) | 0.03 |
| LDH > ULN | 5 (9.0%) | 7 (15.2%) | 0.37 |
| “B” symptoms | 4/53 (7.5%) | 4/43 (9.3%) | 1.00 |
| Follicular Lymphoma Stage | 0.74 | ||
| I | - | - | |
| II | 2 (3.6%) | 3/45 (6.7%) | |
| III | 18 (32.7%) | 16/45 (35.6%) | |
| IV | 35 (63.3%) | 26/45 (57.8%) | |
| FLIPI | 0.97 | ||
| 0–1 | 12/54 (22.2%) | 9/45 (20.0%) | |
| 2 | 24/54 (44.4%) | 20/45 (44.4%) | |
| ≥3 | 18/54 (33.3%) | 16/45 (45.6%) | |
| Histologic grade | 0.82 | ||
| Grade 1 | 30/53 (56.6%) | 27/45 (60.0%) | |
| Grade 2 | 20/53 (37.7%) | 17/45 (37.8%) | |
| Grade 3a | 3/53 (5.7%) | 1/45 (2.2%) | |
| Bone marrow | 0.69 | ||
| Positive | 30 (54.6%) | 23 (50.0%) | |
| Negative | 25 (45.4%) | 23 (50.0%) | |
| Bulky disease | 11/55 (20.0%) | 8/40 (20.0%) | 1.00 |
| ECOG PS | 0.05 | ||
| 0 | 33 (60.0%) | 33/45 (73.3%) | |
| 1 | 22 (40.0%) | 10/45 (22.2%) | |
| 2 | 0 (0.0%) | 2/45 (4.4%) | |
*
P-values for the categorical variables were computed using Fisher’s exact test; the Wilcoxon Rank Sums test was used to compute age differences between groups